Pulse Biosciences, Inc., a clinical-stage medical technology company headquartered in Hayward, California, disclosed in a US Securities and Exchange Commission filing that the company and several of its directors have received subpoenas from the SEC. According to Pulse, the SEC is seeking information about trading of the company’s stock in advance of the financing announcement made by the company in September 2017. Pulse says that it is cooperating with the investigation.
March 14, 2019
Medical technology company discloses SEC investigation
Related by Topic
SEC reaches settlements with two members of an insider trading scheme
April 8, 2026
News Alert
SEC Enforcement | Enforcement Manual Update
March 25, 2026
Insight
SEC adopts final rule that requires foreign insiders to disclose beneficial ownership positions
March 3, 2026
News Alert